Cephalon Sues Eagle Over Plans For Liquid Treanda

Law360, New York (October 23, 2013, 3:07 PM ET) -- Cephalon Inc. hit competitor Eagle Pharmaceuticals Inc. with a suit Monday in a Delaware federal court alleging that Eagle is infringing a Cephalon patent by filing a new drug application for a liquid concentrate version of Cephalon's cancer drug Treanda.

The complaint says that N.J.-based Eagle's filing of a new drug application last month with the U.S. Food and Drug Administration for a liquid version of bendamustine hydrochloride, used to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma, infringes Pa.-based Cephalon's U.S. Patent Number 8,445,524.

“[Cephalon] will...
To view the full article, register now.